Literature DB >> 1973983

GISSI-2 and the heparin controversy.

H D White1.   

Abstract

Mesh:

Substances:

Year:  1990        PMID: 1973983     DOI: 10.1016/0140-6736(90)91818-u

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Thrombolytic treatment for recurrent myocardial infarction.

Authors:  H White
Journal:  BMJ       Date:  1991-02-23

2.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 3.  Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.

Authors:  Michael A Morse; Josh W Todd; George A Stouffer
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

Review 4.  Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.

Authors:  L B Barradell; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

5.  Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.

Authors:  D P de Bono; M L Simoons; J Tijssen; A E Arnold; A Betriu; C Burgersdijk; L López Bescos; E Mueller; M Pfisterer; F Van de Werf
Journal:  Br Heart J       Date:  1992-02

6.  Non-invasive diagnosis of arterial patency after thrombolytic treatment and its relation to prognosis.

Authors:  R M Norris; H D White; D B Cross; K S Woo; J M Elliott; D Twigden; B Williams; R N Johnson
Journal:  Br Heart J       Date:  1993-06

Review 7.  The arterial thrombotic process and emerging drugs for its control.

Authors:  J M Maraganore
Journal:  Tex Heart Inst J       Date:  1993
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.